Latest News

Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report

Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report

Teva Announces Launch of its Generic Erythromycin Tablets USP, Used to Treat or Prevent a Variety of...

Teva Announces Launch of its Generic Erythromycin Tablets USP, Used to Treat or Prevent a Variety of Bact

Teva to Present New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at American Psychiatric Assoc...

Teva to Present New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at American Psychiatric Associatio

Teva Announces the Launch of the First Generic Version of Absorica® (isotretinoin) Capsules, for the...

Teva Announces the Launch of the First Generic Version of Absorica® (isotretinoin) Capsules, for the Trea

Teva Reports First Quarter 2021 Financial Results

Teva Reports First Quarter 2021 Financial Results

Teva to Present New Analyses of AUSTEDO® (deutetrabenazine) Tablets and Assessment of Schizophrenia ...

Teva to Present New Analyses of AUSTEDO® (deutetrabenazine) Tablets and Assessment of Schizophrenia Clini

Teva Announces Launch of its Generic Version of Canasa® (mesalamine) Suppositories To Treat Adults w...

Teva Announces Launch of its Generic Version of Canasa® (mesalamine) Suppositories To Treat Adults with A

New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection and Red...

New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection and Reductio

Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine)...

Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tabl

Teva to Host Conference Call to Discuss First Quarter 2021 Financial Results at 8 a.m. ET on April 2...

Teva to Host Conference Call to Discuss First Quarter 2021 Financial Results at 8 a.m. ET on April 28, 20

Teva Announces Launch of First Generic Version of AZOPT® (brinzolamide ophthalmic suspension) 1%, us...

Teva Announces Launch of First Generic Version of AZOPT® (brinzolamide ophthalmic suspension) 1%, used to

Teva to Present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference

Teva to Present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference

New Study Published in Cephalalgia Identifies Mechanistic Differences Among CGRP Migraine Treatments

New Study Published in Cephalalgia Identifies Mechanistic Differences Among CGRP Migraine Treatments

Teva Reports Fourth Quarter and Full Year 2020 Financial Results

Teva Reports Fourth Quarter and Full Year 2020 Financial Results

Teva Announces Launch of a Generic Version of NuvaRing® (etonogestrel and ethinyl estradiol) Vaginal...

Teva Announces Launch of a Generic Version of NuvaRing® (etonogestrel and ethinyl estradiol) Vaginal Ring

Teva Sets Ambitious Long-Term Environmental Goals As Part of Renewed ESG Strategy

Teva Sets Ambitious Long-Term Environmental Goals As Part of Renewed ESG Strategy

Teva to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results and 2021 Financial Gui...

Teva to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results and 2021 Financial Guidance

Teva to Present at the 39th Annual J.P. Morgan Healthcare Conference

Teva to Present at the 39th Annual J.P. Morgan Healthcare Conference

Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Rele...

Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release S

Teva Reports Third Quarter 2020 Financial Results

Teva Reports Third Quarter 2020 Financial Results

Teva, Amazon Web Services and Onica Announce Collaboration to Support Teva’s Digihaler® Portfolio

Teva, Amazon Web Services and Onica Announce Collaboration to Support Teva’s Digihaler® Portfolio

Teva Announces New Analysis of Consistency in Migraine Days Over the Course of a Dosing Regimen for ...

Teva Announces New Analysis of Consistency in Migraine Days Over the Course of a Dosing Regimen for AJOVY

Teva Launches First Generic Versions of HIV-1 Treatments TRUVADA® (emtricitabine 200 mg/tenofovir di...

Teva Launches First Generic Versions of HIV-1 Treatments TRUVADA® (emtricitabine 200 mg/tenofovir disopro

Teva to Host Conference Call to Discuss Third Quarter 2020 Financial Results at 8 a.m. ET on Novembe...

Teva to Host Conference Call to Discuss Third Quarter 2020 Financial Results at 8 a.m. ET on November 5,

Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salme...

Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol

First Long-Term Data on the use of AJOVY® (fremanezumab-vfrm) Injection in Patients with Migraine Pu...

First Long-Term Data on the use of AJOVY® (fremanezumab-vfrm) Injection in Patients with Migraine Publish

Teva to Present New Data at The MDS Virtual Congress 2020 and Psych Congress 2020 Virtual Experience...

Teva to Present New Data at The MDS Virtual Congress 2020 and Psych Congress 2020 Virtual Experience Eval

Teva to Present New Data on AUSTEDO® (deutetrabenazine) Tablets at the MDS Virtual Congress 2020 and...

Teva to Present New Data on AUSTEDO® (deutetrabenazine) Tablets at the MDS Virtual Congress 2020 and Psyc

Statement in Response to News of the Indictment of Teva USA

Statement in Response to News of the Indictment of Teva USA

Teva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market

Teva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market

Teva Reports Second Quarter 2020 Financial Results

Teva Reports Second Quarter 2020 Financial Results

Teva Announces New Strategic Focus in the Japanese Market

Teva Announces New Strategic Focus in the Japanese Market

Teva Announces New Drug Application Filing in Japan for AJOVY® (fremanezumab) Injection

Teva Announces New Drug Application Filing in Japan for AJOVY® (fremanezumab) Injection

Teva Announces Availability of ProAir® Digihaler® (albuterol sulfate 117 mcg) Inhalation Powder for ...

Teva Announces Availability of ProAir® Digihaler® (albuterol sulfate 117 mcg) Inhalation Powder for Patie

Teva to Host Conference Call to Discuss Second Quarter 2020 Financial Results at 8 a.m. ET on August...

Teva to Host Conference Call to Discuss Second Quarter 2020 Financial Results at 8 a.m. ET on August 5, 2

Teva Presents New Analyses Examining Changes in Migraine Disability Outcome Measurements with AJOVY®...

Teva Presents New Analyses Examining Changes in Migraine Disability Outcome Measurements with AJOVY® (fre

Teva to Present New Data on AJOVY® (fremanezumab-vfrm) Injection Open-Label Extension Study at Ameri...

Teva to Present New Data on AJOVY® (fremanezumab-vfrm) Injection Open-Label Extension Study at American H

Teva Showcases Global Impact in 2019 Environmental, Social and Governance Progress Report

Teva Showcases Global Impact in 2019 Environmental, Social and Governance Progress Report

Teva Announces Virtual 2020 Annual Meeting of Shareholders

Teva Announces Virtual 2020 Annual Meeting of Shareholders

Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY® (fremane...

Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY® (fremanezumab

Teva to Present New AJOVY® (fremanezumab) Analyses and Latest COPAXONE® Data (glatiramer acetate inj...

Teva to Present New AJOVY® (fremanezumab) Analyses and Latest COPAXONE® Data (glatiramer acetate injectio

China Approves AUSTEDO® For Treating Chorea Associated with Huntington's Disease and Tardive Dyskine...

China Approves AUSTEDO® For Treating Chorea Associated with Huntington's Disease and Tardive Dyskinesia i

Teva Reports First Quarter 2020 Financial Results

Teva Reports First Quarter 2020 Financial Results

Teva and Celltrion Healthcare Announce the Launch of TRUXIMA® (rituximab-abbs) Injection for Rheumat...

Teva and Celltrion Healthcare Announce the Launch of TRUXIMA® (rituximab-abbs) Injection for Rheumatoid A

New Data For Teva AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets Inclu...

New Data For Teva AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets Included i

Teva Announces U.S. Launch of Autoinjector for AJOVY® (fremanezumab-vfrm) Injection

Teva Announces U.S. Launch of Autoinjector for AJOVY® (fremanezumab-vfrm) Injection

Teva Drives Positive Impact in Response to COVID-19 Pandemic

Teva Drives Positive Impact in Response to COVID-19 Pandemic

Teva to Host Conference Call to Discuss First Quarter 2020 Financial Results at 8 a.m. ET on May 7, ...

Teva to Host Conference Call to Discuss First Quarter 2020 Financial Results at 8 a.m. ET on May 7, 2020

Teva Statement on Donation of COVID-19 Related Treatments

Teva Statement on Donation of COVID-19 Related Treatments

Teva Update Regarding COVID-19

Teva Update Regarding COVID-19

Teva to Donate Potential COVID-19 Treatment, Hydroxychloroquine Sulfate Tablets to Hospitals Nationw...

Teva to Donate Potential COVID-19 Treatment, Hydroxychloroquine Sulfate Tablets to Hospitals Nationwide